BZI make monitors that track the condition of a patient's brain, continuously at the bedside. Developed in New Zealand they have a partnership with the 1000lb gorrilla of devices GE.
Their gross margins are more than AUD10,000 a unit and they have an 86% take-up rate of their sales model which sees them offer their product for a trial for a two month period.
They have approvals in the US, Europe, and Australasia.
The CEO is an ex-NZ cricket test player who is also a medical doctor and has an MBA, and he's still under 40.
Floated by JT Campbell this company has sensational prospects of blowing away their forecast sales - forecasts that having them recomeding a buy up to $1.00, but still presenting a strong value proposition at $1.50. At 50c currently, they are back at their float price having shot up to the mid 60's soon after listing.
I have posted the research notes on share sc ene. com and encourage you to have a look at them.
Pending announcements are likely to relate to the ramp up of trials in the USA and UK - one's that I expect will blow forecasts away - and also related to a new deal with GE that extends the term of the relationship.
I am well and truely set on this stock, so am unashamaby spruiking it. But it's a great story with a great team behind it.
The main risk: overhang. Tru-test, a troubled NZ electronics manufacturer, owns about 60% of BZI. However I do not see them selling their shares - more likely they'll do an in-specie distribution to their 400 shareholders.
- Forums
- ASX - By Stock
- BZI
- opening post: ground floor entry, going up
opening post: ground floor entry, going up
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BZI (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online